ActiGraph, a maker of wearables and software used by drug companies in clinical trials, on Tuesday announced it acquired the life sciences business of Biofourmis, a digital health startup once considered a unicorn. The eight-figure transaction includes software and algorithms that will allow ActiGraph to expand its offerings.
ActiGraph is known for its smartwatches that capture digital measurements of physical activity and sleep in ways that meet the rigorous standards of drug developers. With Biofourmis, Actigraph will now be able to support a broader set of measures, including blood pressure, weight, blood oxygen and electrocardiographs. ActiGraph will also acquire Biofourmis’ software for remotely ingesting and processing digitally collected data, as well as tools for other clinical-trial needs like monitoring if participants are sticking to protocols and collecting patient-reported outcomes.
The Biofourmis tech adds to ActiGraph’s recent deals with algorithm developers around cough-detection and Parkinson’s symptoms, and CEO Jeremy Wyatt said the company hopes to become a clearinghouse for drug developers looking to use digital tools in their clinical trials.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
